Clinical Characteristics and Treatment Patterns in Patients with Pulmonary Arterial Hypertension (PAH) Initiating Selexipag in the EXPOSURE Observational Study

被引：0
|
作者：
Lange, T. J. [1 ]
Escribano, P. [2 ]
Biedermann, P. [3 ]
Muller, A. [3 ]
Sun, H. [3 ]
Soderberg, S. [4 ]
Gaine, S. [5 ]
机构：
[1] Univ Med Ctr Regensburg, Internal Med 2, Regensburg, Germany
[2] Hosp 12 Octubre, CIBERCV, Dept Cardiol, Pulm Hypertens Unit, Madrid, Spain
[3] Actel Pharmaceut Ltd, Allschwil, Switzerland
[4] Umea Univ, Cardiol & Heart Ctr, Dept Publ Hlth & Clin Med, Umea, Sweden
[5] Mater Misericordiae Univ Hosp, Dublin, Ireland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2910
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Persistence and Predictors of Persistency for Pulmonary Arterial Hypertension (PAH) Patients on Selexipag in Canada: A Retrospective Claims Database Study
    Ibrahim, E.
    Mielniczuk, L.
    Provencher, S.
    Swiston, J.
    Weatherald, J.
    Yip, C.
    Zhang, C.
    Murray, J.
    Badin, M.
    Golden, S.
    Millson, B.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [22] Treatment and survival in patients with pulmonary arterial hypertension (PAH)
    Kremers, Hilal Maradit
    Slusser, Joshua P.
    Scott, Christopher G.
    Primatesta, Paola
    McGoon, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S25 - S25
  • [23] EXPERIENCE OF USING THE DRUG SELEXIPAG IN THE TREATMENT OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
    Karelkina, E. V.
    Goncharova, N. S.
    Simakova, M. A.
    Moiseeva, O. M.
    KARDIOLOGIYA, 2020, 60 (04) : 36 - 42
  • [24] A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension
    Sorensen, Louise M.
    Wehland, Markus
    Krueger, Marcus
    Simonsen, Ulf
    Nassef, Mohamed Z.
    Infanger, Manfred
    Grimm, Daniela
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (34) : 5191 - 5199
  • [25] Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag
    Klose, H.
    Chin, K.
    Ewert, R.
    Gall, H.
    Parambil, J.
    Poch, D.
    Seyfarth, H.
    Axelsen, L.
    Schmitz, S. Hsu
    Stein, C.
    Preston, I.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S490 - S490
  • [26] Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension
    Yazici, Onur
    Gungor, Hasan
    MEANDROS MEDICAL AND DENTAL JOURNAL, 2019, 20 (01): : 1 - 6
  • [27] Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
    Rosenkranz, S.
    Channick, R.
    Chin, K.
    Jenner, B.
    Gaine, S.
    Galie, N.
    Ghofrani, H. A.
    Hoeper, M. M.
    McLaughlin, V. V.
    Preiss, R.
    Rubin, L. J.
    Simonneau, G.
    Sitbon, O.
    Tapson, V.
    Lang, I. M.
    EUROPEAN HEART JOURNAL, 2019, 40 : 3038 - 3038
  • [28] Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension
    Chang, Sung-A
    Lee, Sang Hyun
    Choi, Jung Hyun
    Chung, Wook-Jin
    Choi, Jae Young
    Kim, Hyung-Kwan
    Jung, Hae-Ok
    Park, Seong-Mi
    Kim, Won-Jang
    Jung, Su Young
    Chang, Hyuk-Jae
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (11) : 1423 - 1432
  • [29] Selexipag real-world experience in patients over 75 yrs with pulmonary arterial hypertension (PAH)
    Gaine, Sean
    Escribano, Pilar
    Biedermann, Patricia
    Muller, Audrey
    Sun, Hong
    Soderberg, Stefan
    Lange, Tobias J.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [30] For You to read Selexipag for the Treatment of Pulmonary Arterial Hypertension
    Leitner, H.
    Journal fur Kardiologie, 2016, 23 (9-10): : 249 - 249
12345